Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

American Journal of Hematology

Volumn 89, Issue 10, 2014, Pages 947-953

  Gambacorti Passerini, Carlo ^a   Cortes, Jorge E ^b   Lipton, Jeff H ^c   Dmoszynska, Anna ^d   Wong, Raymond S ^e   Rossiev, Victor ^f   Pavlov, Dmitri ^g   Gogat Marchant, Karin ^g   Duvillié, Ladan ^g   Khattry, Navin ^h   Kantarjian, Hagop M ^b   Brümmendorf, Tim H ^i,j  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f Department of Orthopedics   (Russian Federation)

^g PFIZER INC   (United States)

^h TATA MEMORIAL HOSPITAL   (India)

ⁱ UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIARRHEAL AGENT; ASPARTATE AMINOTRANSFERASE; BICARBONATE; BOSUTINIB; CREATINE KINASE; IMATINIB; TRIACYLGLYCEROL LIPASE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; NITRILE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; CARDIOTOXICITY; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC MYELOID LEUKEMIA; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LUNG METASTASIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEVER; MIDDLE AGED; MULTICENTER STUDY; PAIN; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ALANINE TRANSAMINASE; ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; ASPARTATE AMINOTRANSFERASES; BENZAMIDES; DIARRHEA; FEMALE; FEVER; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUSCLE CRAMP; MYALGIA; NITRILES; PAIN; PIPERAZINES; PYRIMIDINES; QUINOLINES; VOMITING;

EID: 84908028775     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23788     Document Type: Article

References (26)

1. Heisterkamp N, Stam K, Groffen J, et al. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 1985;315:758-761.
2. Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986;233:212-214.
3. Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-1082.
4. ® (nilotinib). Full Prescribing Information, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2013.
5. ® (imatinib mesylate). Full Prescribing Information, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2013.
6. ® (dasatinib). Full Prescribing Information, Bristol-Myers Squibb, Princeton, NJ, 2013.
7. Ohanian M, Cortes J, Kantarjian H, et al. Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother 2012;13:927-938.
8. O'Hare T, Zabriskie MS, Eiring AM, et al. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012;12:513-526.
9. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006;66:11314-11322.
10. Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23:477-485.
11. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110:4055-4063.
12. Cortes JE, Hochhaus A, le Coutre PD, et al. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 2011;117:5600-5606.
13. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119(5):1123-1129.
14. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26:2197-2203.
15. Bosulif (bosutinib). Summary of Product Characteristics, Pfizer Inc, Sandwich, Kent, UK, 2013.
16. Bosulif: EPAR Product Information. European Medicines Agency. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002373/WC500141721.pdf. Accessed February 24, 2014.
17. Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119:3403-3412.
18. Gambacorti-Passerini C, Cortes JE, Khoury HJ, et al. Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200. J Clin Oncol 2010;28(Suppl):Abstract 6509.
19. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012;30:3486-3492.
20. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-884.
21. Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118:4567-4576.
22. Campone M, Bondarenko I, Brincat S, et al. Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol 2012;23:610-617.
23. Daud AI, Krishnamurthi SS, Saleh MN, et al. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res 2012;18:1092-1100.
24. Deininger MW, O'Brien SG, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-1647.
25. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
26. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145.